Aktienanalyse zu Clene Inc (CLNN)CLNNClene Inc

Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Clene Inc. is currently not a strong buy due to its low current price of $3.61, which is significantly below its 52-week high of $11.98, reflecting a 66.94% decline over the past year. The RSI is at 35.79, indicating potential oversold conditions, but the company has reported substantial losses, with a net income loss of $13.42 million in Q2 2026. While there is potential upside based on analyst targets, the significant risks from ongoing operational losses and market volatility suggest a hold position for now.